SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

CV Sciences, Inc. CVSI OTC

Other OTC • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

CV Sciences, Inc. (CVSI) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $0.03. It has a SharesGrow Score of 28/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Financials: revenue is $14M, -5.1%/yr average growth. Net income is $958,000 (loss), growing at +6.9%/yr. Net profit margin is -6.9% (negative). Gross margin is 49% (+14.8 pp trend).

Balance sheet: total debt is $2M against $1M equity (Debt-to-Equity (D/E) ratio 1.1, moderate). Current ratio is 1.03 (adequate). Debt-to-assets is 23.1%. Total assets: $7M.

Analyst outlook: 0 / 4 analysts rate CVSI as buy (0%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 40/100 (Partial), Past 25/100 (Fail), Health 33/100 (Fail), Moat 43/100 (Fail), Future 20/100 (Fail), Income 10/100 (Fail).

CVSI SharesGrow Score Overview

29/100

SharesGrow Score

Below average — proceed with caution

View full scorecard →

VALUE 0/100

Valuation — P/E, PEG, Forward PEG

GROWTH 40/100

Financials — average growth

PAST 25/100

strong — trend

HEALTH 33/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 43/100

Gross margin is + market cap

FUTURE 20/100

Analyst outlook — as buy

INCOME 10/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — CVSI

No analyst coverage available for this stock.

CVSI: -5.1%/yr revenue is, +6.9%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

CVSI: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet CVSI: Debt-to-Equity (D/E) ratio 1.1 (moderate), Current ratio is 1.03 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

CVSI: Gross margin is 49% (+14.8 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 43/100. ≥ 70 = Pass.

View details →

Analyst outlook: 0 / 4 analysts rate CVSI as buy (0%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

CVSI: Net profit margin is -6.9%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range0.02-0.1

Volume223.54K

Avg Volume (30D)1.24M

Market Cap$5.8M

Beta (1Y)0.51

Share Statistics

EPS (TTM)-0.01

Shares Outstanding$184.26M

IPO Date2013-02-12

Employees47

CEOJoseph D. Dowling

Financial Highlights & Ratios

Revenue (TTM)$13.79M

Gross Profit$6.75M

EBITDA$-562K

Net Income$-958K

Operating Income$-992K

Total Cash$278K

Total Debt$1.61M

Net Debt$1.33M

Total Assets$6.96M

Price / Earnings (P/E)-5.8

Price / Sales (P/S)0.42

Analyst Forecast

Rating ConsensusHold

Analysts Covering4

Buy 0% Hold 100% Sell 0%

Company Info

CountryUS

ExchangeOther OTC

CurrencyUSD

ISINUS1266541028

Price Chart

CVSI

CV Sciences, Inc. ↗ · Other OTC

Healthcare • Drug Manufacturers - Specialty & Generic

0.02 52WK RANGE 0.10

People Also View

Charlotte's Web Holdings, Inc.

Cannabis Sativa, Inc.

Trees Corporation

American Cannabis Company, Inc.

Eli Lilly and Company

Johnson & Johnson

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message